CN112353788A

CN112353788A - Application of mexiletine in preparation of medicine for treating cervical spondylosis

Info

Publication number: CN112353788A
Application number: CN202011148717.2A
Authority: CN
Inventors: 张东河
Original assignee: Individual
Current assignee: Individual
Priority date: 2020-10-23
Filing date: 2020-10-23
Publication date: 2021-02-12

Abstract

The invention relates to the technical field of medicaments for treating cervical spondylosis, in particular to application of mexiletine in preparing medicaments for treating cervical spondylosis. The mexiletine disclosed by the invention has an exact curative effect on treating the cervical spondylosis, is suitable for cervical spondylosis patients with different degrees, has a better treatment or alleviation effect on symptoms such as pain, dizziness, nausea, insomnia, palpitation, tinnitus, weakness, soreness and weakness of waist and knees and the like caused by the cervical spondylosis, can effectively treat the cervical spondylosis, and provides a new medicine selection and a new treatment way for treating the cervical spondylosis.

Description

Application of mexiletine in preparation of medicine for treating cervical spondylosis

Technical Field

The invention relates to the technical field of medicaments for treating cervical spondylosis, in particular to application of mexiletine in preparing medicaments for treating cervical spondylosis.

Background

Cervical spondylosis refers to a clinical syndrome of a series of symptoms caused by cervical vertebra hyperosteogeny or intervertebral disc prolapse, ligament thickening stimulation or neck spinal cord, cervical nerves and blood vessels compression due to cervical disc degeneration, cervical hypertrophy and hyperplasia, neck injury and the like. Mainly manifested by neck and shoulder pain, dizziness and headache, numbness of upper limbs, muscular atrophy, spasm of both lower limbs in severe cases, difficulty in walking, and paralysis of limbs, and paralysis of urination and defecation disorder. It is common in the middle-aged and the elderly.

Cervical spondylosis is one of the clinical manifestations of the syndrome of 'poor local microcirculation', because the heart has a little low output capacity and low local effective circulating blood volume, resulting in poor filling degree of small viscera and arterioles of local tissues and poor effective perfusion of the tissues, and then effective and comprehensive qi and blood exchange cannot be carried out. The metabolites of local tissues in the body are accumulated, and toxic and harmful metabolites can not be released into the major circulation, thereby causing the most obvious clinical manifestation of cervical spondylosis.

In the occurrence and development of cervical spondylosis, chronic strain is the chief culprit, and long-term damage to local muscles, ligaments and joint capsules can cause local bleeding and edema, so that inflammation changes occur, inflammation organization gradually occurs at the diseased part, hyperosteogeny is formed, and local nerves and blood vessels are affected. Trauma is a direct factor in the development of cervical spondylosis. People have pathological changes of different degrees before trauma, so that cervical vertebrae are in a high risk state, and trauma directly induces symptoms. Poor posture is another major cause of cervical spine injuries. Dysplasia or defect of cervical vertebrae is also one of the causes of cervical spondylosis. In patients with unilateral vertebral artery insufficiency, the incidence of vertebral artery type cervical spondylosis is almost 100%. The only difference is the question of time. Besides, skull base depression, congenital vertebral fusion, narrow root canal, small spinal canal and the like are all important causes of congenital dysplasia.

The large vessels, nerves and connective tissues in the neck are the only important pathways for the physiological functions of the whole body. The neck motor system is also the key point of the central nervous system for supporting the head, so the physiological burden is large. The middle and small arteriolar blood organs of the neck are sparse relative to other organs or tissues, which is one of the common high-incidence reasons of cervical vertebra patients in the population.

At present, there are many methods for treating cervical spondylosis, including surgical treatment and conservative treatment. The conservative treatment can be acupuncture therapy, massage therapy, physical factor therapy and rehabilitation exercise therapy, and can be matched with medicine conditioning for promoting blood circulation to remove blood stasis and diminishing inflammation and relieving pain, and if the conservative treatment effect is poor, the operation treatment is required.

Mexiletine is a class ib antiarrhythmic drug. It is mainly used for premature ventricular contraction, ventricular tachycardia, ventricular fibrillation, acute myocardial infarction or digitalis-induced arrhythmia.

The patent document with application number 2016800084790 discloses mexiletine in combination with dofilit for the prevention and treatment of atrial fibrillation.

The selection of mexiletine, nackare, baclofen, acamprosate, sulfisoxazole and torasemide for improving memory and related functions such as alertness, attention, concentration, learning and speech processing is disclosed in the patent application No. 2013800524871.

The patent document with application number 2017114310793 discloses a novel composition for the treatment of amyotrophic lateral sclerosis, selected from at least two compounds of cinacalcet, mexiletine, sulfisoxazole, torasemide, riluzole, acamprosate and baclofen or salts, prodrugs, derivatives or sustained release formulations thereof.

Patent document No. 2012800176525 discloses a novel composition for treating neurological disorders, which comprises torasemide, trimetazidine, mexiletine, ifenprodil, moxifloxacin or bromocriptine, or a salt, prodrug, derivative, or sustained release formulation thereof.

At present, no report about mexiletine treatment of cervical spondylosis is found.

Disclosure of Invention

The invention provides an application of mexiletine in preparing a medicament for treating cervical spondylosis, overcomes the defects of the prior art, and discloses the application of mexiletine in treating cervical spondylosis for the first time.

The technical scheme of the invention is realized by the following measures: an application of mexiletine in preparing the medicines for treating cervical spondylopathy is disclosed.

The mexiletine disclosed by the invention has an exact curative effect on treating the cervical spondylosis, is suitable for cervical spondylosis patients with different degrees, has a better treatment or alleviation effect on symptoms such as pain, dizziness, nausea, insomnia, palpitation, tinnitus, weakness, soreness and weakness of waist and knees and the like caused by the cervical spondylosis, can effectively treat the cervical spondylosis, and provides a new medicine selection and a new treatment way for treating the cervical spondylosis.

Detailed Description

The present invention is not limited by the following examples, and specific embodiments may be determined according to the technical solutions and practical situations of the present invention.

The invention is further described below with reference to the following examples:

example (b): the application of mexiletine in preparing medicine for treating cervical spondylosis.

Mexiletine has definite curative effect on cervical spondylosis, is suitable for cervical spondylosis patients with different degrees, and has better treatment or alleviation effect on symptoms such as pain, dizziness, nausea, insomnia, palpitation, tinnitus, hypodynamia, soreness and weakness of waist and knees and the like caused by the cervical spondylosis.

100 patients with cervical spondylosis were treated by oral mexiletine therapy in 70 men and 30 women, aged 30 to 85 years, and the treatment was counted after 3 days. Wherein, effective means that at least one symptom of cervical spondylosis is improved, and ineffective means that no symptom of cervical spondylosis is improved. According to statistics, the number of valid people is 97, and the number of invalid people is 3.

The therapeutic effect of mexiletine on cervical spondylosis will be described below in specific cases.

Auxiliary inspection: cervical vertebra X-ray film, cervical vertebra CT, cervical vertebra MRI, etc.

Diagnosis and identification judgment:

the chief complaints are the main basis, the assistant examination is the assistant, and the following cases exclude the symptoms of cervical spondylosis but other diseases of cervical spondylosis, such as vertigo, aural vertigo, vestibular dysfunction, auditory neuroma and the like. Also, there are brain-derived vertigo and eye-derived vertigo. In addition, neck and shoulder pain and limb pain are also identified with diseases such as stiff neck, scapulohumeral periarthritis, thoracic outlet syndrome, tennis elbow, carpal tunnel syndrome, rheumatic muscle, arthritis, rachitis tumor, etc.

Case one: female, age 54, complained of dizziness, unstable stance, 1 oral mexiletine 50 mg, 1 day 2, treatment 1 day, improvement.

Case two: female, age 63, complaining of dizziness, left neck stiffness and pain for more than a month, blood pressure 170/120 mmHg, oral mexiletine 1 time 50 mg, matching with hypotensive drug, 1 day 2 times, treating for 4 days, improving, and relieving symptoms.

Case three: for men, the patient is 64 years old, the chief complaint is frequently dizziness, accompanied by headache, blurred vision, tinnitus and the like, mexiletine is orally taken for 1 time and 100 mg, 1 day and 3 times, the treatment is carried out for 2 days, the improvement is realized, and the symptoms are relieved.

Case four: for female, 51 years old, complain about weakness of lower limbs, unstable walking, numbness of limbs, 1 time of mexiletine oral administration 100 mg, 1 day of mexiletine oral administration 3 times, treatment 3 days, improvement and symptom relief.

Case five: for men, the disease is cured by 64 years old, mainly complaining neck and shoulder ache, radiating the ache to the head pillow part and the upper limbs, orally taking mexiletine 1 time and 50 mg, 1 day and 2 times, treating for 2 days, improving, and relieving the ache symptom.

Six cases: female, 31 years old, complained of soreness of the neck, shoulders, back and arms, neck stiffness, limited movement, 1 oral administration of mexiletine 50 mg 1 time, 3 times per day for 3 days, and alleviation of the symptoms of soreness.

Case seven: female, 37 years old, complained of dizziness, self-induced house rotation with nausea and vomiting, orally administered mexiletine 1 time 50 mg, 1 day 2 times, treated 1 day, and relieved symptoms.

Eight cases: female, age 45, complained of heavy sensation in the shoulders and back, weakness in the upper limbs, 1 time 50 mg oral mexiletine, 1 day 3 times, 1 day of treatment, improvement and symptom relief.

Nine cases: for men, 30 years old, complain about heavy sensation in the shoulder and back, hand-held object is weak, sometimes unconscious hand-held object falls to the ground, mexiletine is orally taken for 1 time and 100 mg, 1 day and 3 times, treatment is carried out for 5 days, improvement is carried out, and symptoms are relieved.

Ten cases: for men, the age of 68 years old mainly complains of cervical spondylosis for years, acupuncture and massage and other treatments have no obvious effect, and symptoms are relieved after 1 mexiletine is orally taken for 50 mg, 1 mexiletine is orally taken for 3 times and 3 days are treated.

Many cases, not described herein, can relieve or even completely cure the cervical spondylosis when mexiletine is used for treating the cervical spondylosis. Many cases, not described herein, can relieve or even completely cure the cervical spondylosis when mexiletine is used for treating the cervical spondylosis.

The technical characteristics form an embodiment of the invention, which has strong adaptability and implementation effect, and unnecessary technical characteristics can be increased or decreased according to actual needs to meet the requirements of different situations.

Claims

1. An application of mexiletine in preparing the medicines for treating cervical spondylopathy is disclosed.